Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy SpringWorks Therapeutics stock

Learn how to easily invest in SpringWorks Therapeutics stock.

SpringWorks Therapeutics Inc is a biotechnology business based in the US. SpringWorks Therapeutics shares (SWTX) are listed on the NASDAQ and all prices are listed in US Dollars. SpringWorks Therapeutics employs 190 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in SpringWorks Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – SWTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

SpringWorks Therapeutics stock price (NASDAQ: SWTX)

Use our graph to track the performance of SWTX stocks over time.

SpringWorks Therapeutics shares at a glance

Information last updated 2022-07-01.
Latest market close$26.52
52-week range$13.60 - $89.75
50-day moving average $32.16
200-day moving average $54.41
Wall St. target price$76.25
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-4.23

Buy SpringWorks Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$1
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Axos Bank Self Directed Investing
Stocks
$0
$1,000
$150
when you open an account and deposit at least $1500.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy SpringWorks Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

SpringWorks Therapeutics price performance over time

Historical closes compared with the close of $26.52 from 2022-07-01

1 week (2022-06-24) 3.39%
1 month (2022-06-03) 22.83%
3 months (2022-03-30) N/A
6 months (2021-12-30) -57.45%
1 year (2021-07-02) -69.21%
2 years (2020-07-02) -34.60%
3 years (2019-06-29) N/A
5 years (2017-06-29) N/A

SpringWorks Therapeutics financials

Revenue TTM $35 million
Gross profit TTM $35 million
Return on assets TTM -26.71%
Return on equity TTM -45.18%
Profit margin 0%
Book value $7.70
Market capitalisation $1.3 billion

TTM: trailing 12 months

SpringWorks Therapeutics share dividends

We're not expecting SpringWorks Therapeutics to pay a dividend over the next 12 months.

SpringWorks Therapeutics share price volatility

Over the last 12 months, SpringWorks Therapeutics's shares have ranged in value from as little as $13.6 up to $89.746. A popular way to gauge a stock's volatility is its "beta".

SWTX.US volatility(beta: 1.08)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while SpringWorks Therapeutics's is 1.0756. This would suggest that SpringWorks Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

SpringWorks Therapeutics overview

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd. , GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc.

Frequently asked questions

What percentage of SpringWorks Therapeutics is owned by insiders or institutions?
Currently 9.336% of SpringWorks Therapeutics shares are held by insiders and 101.214% by institutions.
How many people work for SpringWorks Therapeutics?
Latest data suggests 190 work at SpringWorks Therapeutics.
When does the fiscal year end for SpringWorks Therapeutics?
SpringWorks Therapeutics's fiscal year ends in December.
Where is SpringWorks Therapeutics based?
SpringWorks Therapeutics's address is: 100 Washington Boulevard, Stamford, CT, United States, 06902
What is SpringWorks Therapeutics's ISIN number?
SpringWorks Therapeutics's international securities identification number is: US85205L1070
What is SpringWorks Therapeutics's CUSIP number?
SpringWorks Therapeutics's Committee on Uniform Securities Identification Procedures number is: 844909101

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site